Treatment of Fibrosis

Dermal fibrosis is a consequence of an exaggerated healing response in the dermis, with a disproportionate fibroblast proliferation and disorganized extracellular matrix ECM production. Clinically, skin fibrosis manifests as thickened, tightened, and hardened areas of skin. Ultimately, skin fibrosis may lead to dermal contractures that affect the ability to flex and extend the joints. 


The wide spectrum of fibrotic skin diseases may be caused by immune or inflammatory mechanisms, as well as surgery and exposure to chemicals.


Since fibrosis is often preceded and accompanied by chronic inflammation, it has been assumed for a long time that inflammation is a necessary contributor to fibrosis.

Normally, an injury to the skin tissues causes a rapid (within hours) early acute inflammatory response, followed by the late- phase inflammation (within days since the injury), and finally followed by a healing response (within weeks).


During this latter phase fibroblasts become activated, undergo phenotypic transformation and cause wound contraction. They also proliferate and accelerate production of ECM components (particularly collagen), leading to formation of a scar.


The processes outlined in the figure below are controlled by cytokines, many of which will stimulate or inhibit fibroblast proliferation and collagen production.


BSERUM HA1.5 is a special type of High Molecular Weight Hyaluronic Acid (HMWHA) which has been specifically designed for the treatment and prevention of FIBROSIS.

It has anti-inflammatory and regenerative properties and stimulates collagen fibers reshaping in damaged tissues.


Thanks to its unique characteristics, it is used to fight against the hyper-proliferation of fibroblasts, inhibit pro-fibrotic factors and stimulate the reorganization of the collagen matrix in the dermis, constituting the basis of PBSERUM MEDICAL treatments.



PBSerum | 06/03/2020

leave a reply

  • Name*